**2019 surveillance –** [**Obsessive-compulsive disorder and body dysmorphic disorder: treatment**](https://www.nice.org.uk/guidance/cg31) **(2005) NICE guideline CG31**

**Stakeholder consultation comments form - proposal ‘to update’**

Consultation on the proposal ‘to update’opens at: 9am, Wednesday 9 January 2019

Comments on proposal to be submitted: no later than 5pm, Tuesday 22 January 2019

|  |
| --- |
| **Please enter the name of your registered stakeholder or respondent organisation below.**Please use this form for submitting your comments to NICE. 1. Please put each new comment in a new row.
2. Please note – we cannot accept comments forms with attachments such as research articles, letters or leaflets. If we receive forms with attachments we will return them without reading the comments. If you resubmit the comments on a form without attachments, this must be by the consultation deadline.
3. If you wish to draw our attention to published studies, please supply the full reference.
4. If you’re commenting for an organisation, your organisation needs to be [registered as a stakeholder](https://www.nice.org.uk/get-involved/stakeholder-registration).

Not eligible? Contact the [registered stakeholder organisation](https://www.nice.org.uk/guidance/cg31/documents/stakeholder-list-2) that most closely represents your interests and pass your comments to them.We can accept comments from individuals. These will be considered, but you won’t get a formal response and they won’t be posted on the NICE website. Wherever possible we encourage you to submit your comments through a registered stakeholder organisation. |
| Organisation name – Stakeholder or respondent (if you are commenting as an individual rather than a registered stakeholder or respondent organisation, please leave blank): |  |
| DisclosurePlease disclose whether the organisation has any past or current, direct or indirect links to, or receives funding from, the tobacco industry. |  |
| Name of commentator: |  |

[Developing NICE guidelines: the manual](https://www.nice.org.uk/process/pmg20/chapter/1-introduction-and-overview) gives an overview of the processes used in surveillance reviews of NICE clinical guidelines.

| **ID** | **Questions**  | **Overall response**yes / no | **Comments**Please insert each new comment in a new row |
| --- | --- | --- | --- |
| 1 | Do you agree with the proposal to update the guideline? |  |  |
| 2 | Is transcranial magnetic stimulation treatment currently used in clinical practice for treatment of obsessive compulsive disorder (OCD)? Are you aware of any evidence relating to this intervention? |  |  |
| 3 | In practice, are SSRIs increasingly being used as a first-line treatment for young people with OCD? |  |  |
| 4 | How often people with OCD are referred to IAPTS (improving access to psychological therapies services) and are there any barriers with access to treatment offered through IAPTS? |  |  |
| 5 | Does the stepped care pathway in CG31 need reconsideration? If so, why? |  |  |
| 6 | Is ego-dystonic paedophilic or violent thoughts and images a reasonable consideration in risk assessment for individuals with OCD? |  |  |
| 7 | Do you have any comments on areas excluded from the scope of the guideline? |  |  |
| 8 | Do you have any comments on equalities issues? |  |  |

**Please email this form to:** **surveillance@nice.org.uk**

**Closing date: Tuesday, 22 January 2019**

**PLEASE NOTE:** NICE reserves the right to summarise and edit comments received during consultations, or not to publish them at all, if NICE’s reasonable opinion is that the comments are voluminous, publication would be unlawful or publication would be otherwise inappropriate.